Hepatitis A seroprevalence in patients with chronic viral hepatitis in Konya, Turkey by Ozden, Hale T.
Hepatitis A seroprevalence in patients with chronic
viral hepatitis in Konya, Turkey
Hale T. Özden
Aim Hepatitis A is among the diseases that can be prevented with vaccination in our time. Acute hepatitis A progresses more
severely in individuals with a liver disease. Therefore, patients with a chronic liver disease (because of hepatitis B or hepatitis C)
are advised vaccination with the hepatitis A vaccine. This study is aimed to determine the seroprevalence of hepatitis A virus
(HAV) antibodies in patients infected with hepatitis C virus or hepatitis B virus in Konya province of Turkey.
Methods A total of 537 patients who had chronic viral hepatitis between January 2011 and December 2014 were included in
the study. Serum samples were collected from each patient and tested for anti-HAV using the chemiluminescent microparticle
immunoassay.
Results The overall seroprevalence of total anti-HAV IgG was 94.2%. The overall prevalence of anti-HAV IgG in patients with
chronic hepatitis B virus and hepatitis C virus infection was 97.5 and 93.6%, respectively. Anti-HAV IgG positivity was 97.4% in
cirrhotic patients and 93.9% in noncirrhotic individuals.
Conclusion At the end of the study, being older than 40 years and living in a rural area were found to be independent risk factors
for anti-HAV IgG seropositivity. In conclusion, we recommend that patients younger than 40 years and/or those living in cities and
having a chronic liver disease should be vaccinated with the hepatitis A vaccine. Eur J Gastroenterol Hepatol 28:333–337
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Acute viral hepatitis A, which is caused by the hepatitis A
virus (HAV), is an infectious disease that is prevalent
worldwide, but more in underdeveloped and developing
countries, and which can be prevented through vaccina-
tion. It is the most common cause of hepatitis worldwide
[1]. Although it is usually asymptomatic and subclinical in
children, it can appear in a variety of clinical forms ranging
from a mild flu-like condition to a fulminant hepatitis [2].
A severe disease and fulminant liver failure because of
HAV may occur in adulthood or in the elderly population
and in patients with chronic liver disease (CLD) [3].
Although the seroprevalence of anti-HAV IgG has
decreased in many countries, it is still quite high in
underdeveloped countries [4]. The HAV seroprevalence is
known to increase as much as 100% before 10 years of age
in regions with a high endemicity, whereas in regions with
moderate and low endemicity, this rate is around 10%
until mid-adolescence [5]. Turkey is in the moderately
endemic group in terms of the epidemiology of HAV
infection. The most recent data show that the HAV is still
widely circulating endemically in our country, but the age
of encountering the virus shifts towards adolescence and
young adulthood particularly in the Western Anatolia
region of our country and in other regions of higher
socioeconomic level [6]. Decreasing hepatitis A incidence
in line with accelerating development in our country
makes vaccination against HAV more important in CLD
patients who are at risk. Clean water and food, adherence
to personal hygiene practices, and vaccination with the
hepatitis A vaccine are important for protection from
hepatitis A infection.
Konya is a province located in the Central Anatolia
region of our country. Its socioeconomic status is better
compared with the provinces in Eastern Anatolia and
moderate compared with the provinces in Western
Anatolia. The present study explores the rates of exposure
to HAV by age groups and the need for vaccination in
patients being monitored for chronic viral hepatitis diag-
nosis in our province.
Materials and methods
We included 537 individuals in our study who presented
between January 2011 and December 2014 to the
Infectious Diseases and Clinical Microbiology Outpatient
Clinic of Baskent University Konya Medical and Research
Hospital and who were diagnosed with chronic hepatitis B
or chronic hepatitis C and/or liver cirrhosis. Patients
whose hepatitis B surface antigen (HBsAg) was positive for
6 months and those whose hepatitis C virus antibody (anti-
HCV) and HCV-RNA value were positive twice within an
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interval of at least 6 months were enrolled in the study.
Patients who had received the hepatitis A vaccine pre-
viously and those who had nonviral or autoimmune
hepatitis were excluded from the study. The status of
underlying liver disease was classified into chronic hepa-
titis and liver cirrhosis. The diagnosis of liver cirrhosis was
made if any one of the following findings was encountered:
(i) compatible intraoperative gross findings or histologi-
cally compatible findings; (ii) evidence of portal hyper-
tension in patients with liver disease; and (iii) compatible
radiologic findings and platelet counts less than 100 000/
mm3.
Blood samples of 10ml were obtained from each
patient. The samples were analyzed for the HBsAg, anti-
HCV, and anti-HAV IgG parameters using the chemilu-
minescent microparticle immunoassay method in line with
the procedure suggested by the manufacturing company
(Architect i2000; Abbott Diagnostics, Abbott Park,
Illinois, USA). Recurrent reactive results were considered
positive. HCV-RNA detection in serum samples was per-
formed using real-time PCR with a commercial kit
(Fluorion; Iontek, Istanbul, Turkey). For RNA extraction,
the QIAamp, Viral RNA Mini Extraction Kit (Qiagen,
Hilden, Germany) was used in accordance with the
instructions of the manufacturer.
The distribution of the patients by age and sex was
assessed. The patients were divided into age groups of
10 years each.
Statistical analysis
The data were statistically analyzed using the SPSS (ver-
sion 15.0; SPSS Inc., Chicago, Illinois, USA) statistical
program. The data were described as numbers, percen-
tages, and mean ± SD. The χ2-test was used for qualitative
changes and Student’s t-test, one-way ANOVA, and var-
iance analysis were used for quantitative changes when
assessing the data. A χ2-test was used to determine whether
significant differences existed between two categorical
variables. For multivariate analyses, a stepwise multi-
variate logistic regression model was used to assess the
relative importance of variables showing a significant
association (P<0.05). The results of all multivariable
analyses were reported as adjusted odds ratio, 95% con-
fidence interval, and exact P value.
Results
A total of 537 patients were included in the study. A total
of 437 patients were diagnosed with chronic hepatitis B,
60 with chronic hepatitis C, 18 with liver cirrhosis asso-
ciated with chronic hepatitis B, and 22 with liver cirrhosis
associated with chronic hepatitis C. A total of 297
(55.3%) of the patients were men and 240 (44.7%) were
women. Their mean age was 45.9 ±14 years (15–81 years).
Anti-HAV IgG was found to be positive in 506 (94.2%)
patients and negative in 31 (5.8%) patients. The demo-
graphic characteristics of the patients are shown in
Table 1.
When the study participants were classified by decade
of age into seven groups, from less than 20 years to older
than 70 years old, most of the chronic hepatitis patients
were found to be in the 51–60 age interval and 64.6% of
them were 40 years of age and older. Anti-HAV IgG ser-
opositivity was 23.8% in the age group younger than
20 years, 82% in the 21–30 age group, and 90.5% in the
31–40 age group. The positivity rate for anti-HAV in the
patients in their 40, 50, 60s, and those older than 71 years
was 100, 99.1, 100, and 100%, respectively (Fig. 1). Anti-
HAV IgG seropositivity in chronic hepatitis B and chronic
hepatitis C patients is shown in Table 2 by age groups. The
anti-HAV seroprevalence was significantly higher in
patients older than 40 years compared with those patients
younger than 40 years of age (99.7 vs. 80.4%, respec-
tively, P< 0.05) (Table 3).
Anti-HAV IgG seropositivity was found in 94.3% of
male patients and 94.2% in female patients, and the dif-
ference was not statistically significant (P>0.05; Table 3).
With respect to the etiology of liver disease and the status
of liver disease, anti-HAV IgG was positive in 93.6% of
the chronic hepatitis B patients and in 97.5% of the
Table 1. Patients’ characteristics
N (%)
Age [mean (range)] (years) 45.9 ± 14 (15–81)
Sex
Female 240 (44.7)
Male 297 (55.3)
Etiology of liver disease
Chronic viral hepatitis B 437 (81.4)
Chronic viral hepatitis C 60 (11.2)
HBV-related liver cirrhosis 18 (3.4)
HCV-related liver cirrhosis 22 (4)
Place of residence
City 302 (56.3)
Town 194 (36.1)
Rural area 41 (7.6)
Prevalence of IgG HAV 506 (94.2)
HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus.
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Fig. 1. Prevalence of IgG anti-hepatitis A virus according to age in patients
with chronic viral liver disease.
Table 2. Prevalence of IgG anti-hepatitis A virus in patients with hepatitis
B versus those with hepatitis C virus infection [n (%)]
Age (years) Anti-HAV/HBV Anti-HAV/HCV
<20 5/21 (23.8) 0
21–30 64/77 (83.2) 0/1 (0)
31–40 92/102 (90.2) 2/3 (66.7)
41–50 110/110 (100) 4/4 (100)
51–60 92/93 (98.9) 30/30 (100)
61–70 46/46 (100) 31/31 (100)
>70 6/6 (100) 13/13 (100)
HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus.
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chronic hepatitis C patients (P>0.05). Anti-HAV IgG
positivity was found to be 97.4% in cirrhotic patients and
93.9% in noncirrhotic patients, the difference being sta-
tistically insignificant (Table 3).
With respect to the residences of the patients with
chronic viral hepatitis, anti-HAV IgG positivity was found
to be significantly higher in those living in rural areas than
in patients living in cities (P< 0.05; Table 3).
Multivariable analysis of the factors for anti-HAV ser-
opositivity is shown in Table 3. At the end of the study,
being older than 40 years and living in a rural area were
found to be independent risk factors for anti-HAV IgG
seropositivity.
Two doses (at months 0 and 6) of the hepatitis A vac-
cine were administered to 21 of the 31 patients who had
been found to be anti-HAV IgG negative. Only eight of
these 21 patients could be examined for the outcome and
anti-HAV IgG was found to be positive in all of them.
Discussion
Developing countries are currently facing a change in the
epidemiological pattern of HAV infection. Improved
socioeconomic statuses, more sanitary environments, and
advanced hygienic practices all play a role in steadily
reducing the incidence of HAV infection and age-specific
HAV seroprevalence in the general population. Declining
HAV infections particularly in young adults have led to a
decrease in the number of individuals with protective
antibodies, resulting in an increase in the prevalence of
hepatitis A in this population [7]. With the improvements
in the sanitation and hygiene conditions in our country in
recent years, the age of exposure to hepatitis A has been
reported to shift from childhood to adolescent or adult age
groups [5]. The statistical works carried out by the
Ministry of Health between 1990 and 2005 show that the
incidence of hepatitis A infections has decreased from
5325/100 000 to 1281/100 000 and the rate of mortality
has decreased from 0.78/1 000 000 to 0.03/1 000 000 [8].
In a recent multicentered study carried out in our
country, but that did not include the province of Konya,
4793 patients with chronic hepatitis B were investigated
and the rate of anti-HAV IgG positivity was found to be
93.5% [9]. This rate is very close to the rate of anti-HAV
IgG positivity that we found in chronic hepatitis B patients,
which was 93.6%.
The anti-HAV IgG seropositivity in patients with a
CLD has been reported in largely varying rates in the
studies carried out in various countries of the world. In
three different studies carried out in Italy on patients with
a CLD, anti-HAV IgG seropositivity has been reported to
be 79.3% [10] and 85.7% [11], and 97.64% in patients
with chronic hepatitis C only [12]. In another multicenter
study carried out in Italy, the rate of anti-HAV IgG ser-
opositivity was 53.5% in 2830 patients with a CLD, the
rate being higher in the south and middle provinces of the
country and lower in the north [13]. The anti-HAV IgG
seropositivity was 55% in patients with a CLD in the USA,
another developed country [14].
In a study carried out in Saudi Arabia, anti-HAV IgG
positivity was found to be as high as 98.5% in a group of
136 CLD patients whose mean age was 39.1 ±17.6 years
and it was concluded at the end of the study that the
hepatitis A vaccine was not necessary for adult patients
with CLD [15].
In another study carried out in the Kerala region of
India, anti-HAV IgG positivity was found to be 93.3% in
300 CLD patients whose mean age was 53 ±4 years, and at
the end of the study it was suggested that routine vacci-
nation should not be attempted before anti-HAV IgG was
tested [16].
Anti-HAV IgG positivity was found to be 98.1% in
adult patients with liver cirrhosis in Brazil and no routine
vaccination was recommended at the end of the study [17].
In a study carried out in Iran, the anti-HAV IgG posi-
tivity was 79.2% in patients with chronic viral hepatitis,
and hepatitis A vaccination was recommended for patients
with chronic viral hepatitis who were younger than
30 years old [18].
A large number of studies have been carried out in
Korea on this subject [19–24]. In one of the two recent
studies, the anti-HAV IgG positivity was found to be
86.61% in patients with chronic viral hepatitis [19] and
the anti-HAV IgG positivity was found at to be 49.1% in
the other study where only patients with chronic hepatitis
B were assessed [20].
At the end of the study, being older than 40 years and
living in a rural area were found to be independent risk
factors for anti-HAV IgG seropositivity. The anti-HAV
IgG positivity was found to be statistically higher in our
study in patients older than 40 years compared with those
younger than 40 years of age. Although an age above
40 years was found to be a risk factor for anti-HAV IgG
seropositivity in the Korean study [19], the anti-HAV IgG
seropositivity was found to be significantly higher in
chronic hepatitis patients older than 30 years of age in a
study carried out in Iran [18]. A study carried out by Saab
et al. [14] in the USA has shown that patients aged
between 51 and 70 years have a higher risk of being
exposed to HAV than patients younger than 51 years of
age. Studies have shown that the ages at which individuals
Table 3. Factors affecting seropositivity for IgG anti-hepatitis A virus in
the multivariate analysis
Characteristics
Anti-HAV IgG positivity [n
(%)] OR (95% CI) P value
Age (≥40 years) 346/347 (99.7) 64.87 (8.8–480) < 0.05
Sex 0.98 (0.47–2.03) >0.05
Female 280/297 (94.3)
Male 226/240 (94.2)
Etiology of liver
disease
0.37 (0.09–1.57) >0.05
HBV 426/455 (93.6)
HCV 80/82 (97.5)
Status of liver
disease
0.42 (0.06–3.2) >0.05
Chronic viral
hepatitis
469/499 (93.9)
Liver cirrhosis 37/38 (97.4)
Place of residence < 0.05
City 238/260 (91.5)
Town 154/161 (95.6)
Rural area 34/34 (100)
Bold font indicates statistical significance.
CI, confidence interval; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV,
hepatitis C virus; OR, odds ratio.
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become infected have been shifting from young to old in
developing countries [25,26].
When anti-HAV IgG positivity was assessed in terms of
sex, no difference was found in most of the studies as in
our study [13,14,20,21], but there are also study results
showing that female sex is an independent risk factor
[18,19]. More anti-HAV IgG seropositivity was found in
female patients in the study carried out in Korea. They
explained this finding by the fact that female patients in
Korea have a larger number of social and household
contacts and thus probably more exposure to HAV [19].
With respect to place of residence, we found in our
study that living in a rural area was an independent risk
factor for anti-HAV IgG seropositivity. Although in the
study carried out in Korea the anti-HAV IgG sero-
prevalence was found to be the lowest in Seoul, the most
developed city of Korea, the rate was found to be higher in
rural areas as in our study [19]. In the study carried out in
Italy, seroprevalence was found to be higher in the South
of Italy than in the North and this was linked to improving
hygiene and socioeconomic conditions in Northern Italy
[13]. Such variances in seroprevalence may be associated
with differences in living conditions.
No correlation was found in the present study between
anti-HAV IgG seropositivity and hepatitis B/hepatitis C.
This result is in agreement with those of other studies [14,
18,19]. This finding may indicate that the immune
response to HAV infection is not affected by either hepa-
titis B virus or HCV.
There was also no difference between cirrhotic and
noncirrhotic patients with respect to anti-HAV IgG ser-
opositivity. However, the results of some studies indicate
that the anti-HAV IgG seropositivity is higher in patients
with liver cirrhosis than in those with chronic viral hepa-
titis [18,19]. They point out that the higher seropositivity
of anti-HAV in older individuals may be explained by the
fact that they lacked good hygiene practices in the past and
were probably exposed to HAV, leading to the production
of anti-HAV [18]. The result that we found may be linked
to the fact that the number of cirrhotic patients was
smaller than the number of patients with chronic hepatitis
in our study.
Two doses (at months 0 and 6) of the hepatitis A vac-
cine were administered to 21 of the 31 patients who had
been found to be anti-HAV IgG negative. Only eight of
these 21 patients could be examined for the outcome and
anti-HAV IgG was found to be positive in all of them. In a
study, the IgG seroconversion was found to be 86.17% in
patients with chronic hepatitis B after their hepatitis A
vaccination [27]. However, no interpretation was
attempted in this study on this issue because we could not
vaccinate all the chronic viral hepatitis patients who were
anti-HAV IgG negative and not all the patients that we
could vaccinate attended follow-up.
Hepatitis A vaccines, which had initially been licensed
to be used after age 2 as maternal antibodies showed
persistence, were licensed by the Food and Drug
Administration (FDA) after 2005 to be administered to
children older than a year. Hepatitis A vaccine is recom-
mended in the USA today for all children older than 1 year
[28]. In 2012, the Ministry of Health in Turkey included
the hepatitis A vaccine in the routine vaccination program
to be administered at the end of month 18 as the first dose
and at the end of month 24 as the second in infancy [6].
This routine vaccination program is good news for the
coming years for our country, which is in moderate
endemicity for particularly chronic hepatitis B.
In conclusion, patients with CLD who are younger than
40 and/or living in cities may be at risk for hepatitis A
infection. Such patients should be advised to seek hepatitis
A vaccination following an anti-HAV IgG test.
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